Shanshan Huang

Mrs. Shanshan Huang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YYYunkai Yang
Yunkai Yang
HZHuan Zhang
Huan Zhang
SHShanshan Huang
Shanshan Huang
QCQian Chu
Qian Chu
Kristen rat sarcoma (KRAS) gene is one of the most common mutated oncogenes in solid tumors. Yet, KRAS inhibitors did not follow suit with the development of targeted therapy, for the structure of KRAS has been considered as being implausible to target for decades. Chemotherapy was the initial recommended therapy for KRAS-mutant cancer patients, which was then replaced by or combined with immunotherapy. KRAS G12C inhibitors became the most recent breakthrough in targeted therapy, with Sotorasib being approved by the Food and Drug Administration (FDA) based on its significant efficacy in multiple clinical studies. However, the subtypes of the KRAS mutations are complex, and the development of inhibitors targeting non-G12C subtypes is still at a relatively early stage. In addition, the monotherapy of KRAS inhibitors has accumulated possible resistance, acquiring the exploration of combination therapies or next-generation KRAS inhibitors. Thus, other non-target, conventional therapies have also been considered as being promising. Here in this review, we went through the characteristics of KRAS mutations in cancer patients, and the prognostic effect that it poses on different therapies and advanced therapeutic strategy, as well as cutting-edge research on the mechanisms of drug resistance, tumor development, and the immune microenvironment.

26 August 2025 in Cellular Oncology
Verified
Journal Article
Open access
PDF file
CYChenxi Yan
Chenxi Yan
YCYanjie Chen
Yanjie Chen
YTYitao Tian
Yitao Tian
SHShaojie Hu
Shaojie Hu
HWHeng Wang
Heng Wang
WSWei Sun
Wei Sun
Lung cancer remains the leading cause of cancer-related mortality worldwide, with limited treatment efficacy and frequent resistance to conventional therapies. Recent advances have uncovered the critical influence of the human microbiota—complex communities of bacteria, viruses, fungi, and other microorganisms—on lung cancer pathogenesis and therapeutic responses. This review synthesizes current knowledge on the compositional and functional roles of microbiota across multiple body sites, including the gut, lung, tumor microenvironment, circulation, and oral cavity, highlighting their contributions to tumor initiation, progression, metastasis, and immune regulation. We emphasize the bidirectional communication between microbial metabolites and host immune pathways, particularly the gut–lung axis, which modulates systemic and local antitumor immunity. Importantly, microbiota composition has been linked to differential responses and toxicities in chemotherapy, radiotherapy, targeted therapy, and immune checkpoint blockade. Microbiota-targeted interventions, such as probiotics, fecal microbiota transplantation, and selective antibiotics, show promising potential to enhance treatment efficacy and mitigate adverse effects. However, challenges remain in clinical translation due to interindividual microbiome variability, mechanistic complexities, and limited longitudinal data. Future research integrating multi-omics, microbial functional profiling, and controlled clinical trials is essential to harness the microbiome as a precision medicine tool in lung cancer management. This review provides a comprehensive overview of the emerging role of microbiota in lung cancer development and therapy, offering new perspectives for innovative therapeutic strategies.

1 August 2024 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
XLXuchang Li
Xuchang Li
YXYangchen Xia
Yangchen Xia
CWChengyan Wang
Chengyan Wang
SHShanshan Huang
Shanshan Huang
QCQian Chu
Qian Chu
Background: A previous network meta-analysis (NMA) compared the efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK-positive non-small cell lung cancer (NSCLC). The phase III INSPIRE study of iruplinalkib was published recently. The present study aimed to add the results related to iruplinalkib to the NMA. Methods: A systematic literature search was performed in PubMed, Embase, Cochrane Library, Google, and Baidu. Randomized controlled trials (RCTs) reporting the independent review committee-assessed progression-free survival (PFS), objective response rate (ORR), or disease control rate (DCR) results of Asian patients with ALK inhibitor-naïve advanced ALK-positive NSCLC were eligible for inclusion in the NMA. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Bayesian fixed-effect models were used for the direct and indirect pairwise comparisons. This study was registered with PROSPERO (CRD42024555299). Results: Eight studies, involving 1,477 Asian patients and seven treatments (crizotinib, alectinib, brigatinib, ensartinib, envonalkib, iruplinalkib, and lorlatinib), were included in the NMA. In terms of the overall risks of bias, all of the studies had “some concerns”. All the next-generation ALK inhibitors were statistically superior to crizotinib in terms of PFS. Iruplinalkib had the best surface under the cumulative ranking curve (74.0%), followed by brigatinib (69.1%) and ensartinib (63.7%). Most of the pairwise comparisons did not reveal significant differences in the ORR and DCR. In terms of both the ORR and DCR, alectinib ranked first, followed by lorlatinib. Conclusions: Next-generation ALK inhibitors had better efficacy than crizotinib in the treatment of Asian patients with ALK inhibitor-naïve advanced ALK-positive NSCLC. Iruplinalkib may have more favorable PFS benefit than other ALK inhibitors for Asians.

12 January 2026 in iScience
Verified
Journal Article
Open access
ZXZhaolin Xu
Zhaolin Xu
FLFangfang Liu
Fangfang Liu
SHShanshan Huang
Shanshan Huang
QCQian Chu
Qian Chu
Cellular senescence (CS) shapes lung cancer biology by enforcing durable growth arrest while remodeling the tumor immune microenvironment (TIME) through the senescence-associated secretory phenotype (SASP). In non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) have improved outcomes, and senescence programs can influence antigen presentation, immune cell recruitment, and adaptive resistance. This review integrates evidence from cell and animal models, patient-derived datasets, and early clinical studies to map senescent cell states across cancer immunoediting and treatment contexts. We summarize senescence phenotypes in tumor and stromal compartments, highlight SASP-driven immune modulation, and discuss senescence-linked biomarkers that may inform prognosis and therapy selection. We also evaluate emerging senotherapeutic strategies—senolytics, prodrug approaches, and SASP-modulating senomorphics—designed to pair senescence induction with selective clearance or reprogramming. Together, these concepts frame a testable “induce, then edit or eliminate” paradigm to improve durability of lung cancer therapies.

9 June 2026 in Chinese Medical Journal Pulmonary and Critical Care Medicine
Verified
Journal Article
Open access
ZXZiyang Xu
Ziyang Xu
SHShanshan Huang
Shanshan Huang
QCQian Chu
Qian Chu
Reciprocal crosstalk between the nervous system and malignancies is increasingly recognized as a key regulator of tumor progression across solid cancers. Neuronal activity and nerve infiltration can shape tumor growth, immune tone, and metastatic behavior through paracrine signaling and, in selected contexts, synapse-like interactions. However, how neural circuits regulate lung cancer progression remains insufficiently defined. β-adrenergic blockade has been reported to be associated with reduced lung tumor growth and metastatic potential in multiple settings, highlighting the clinical relevance of innervation. Here we synthesize emerging evidence on lung cancer–nerve crosstalk from the perspective of cancer neuroscience, focusing on neural remodeling in the tumor microenvironment, mechanisms underlying tumorigenesis and metastasis, the neuro–immune–tumor axis, and translational opportunities for neuro-modulatory interventions. This review provides an integrated framework to inform future mechanistic studies and the development of therapeutically actionable targets.